-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Condemn Productivity Commission Inquiry for Excluding Tax and Labor Issues
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Sheikh Hasina Vows Return to Bangladesh Despite Death Sentence
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
-
Alex Bodi byl jmenován viceprezidentem skupiny SCANDIC FINANCE
-
Alex Bodi utsedd till vicepresident för SCANDIC FINANCE-koncernen
-
تعيين أليكس بودي نائبًا لرئيس مجموعة SCANDIC FINANCE
-
SCANDIC FINANCEグループ、アレックス・ボディ氏を副社長に任命
-
SCANDIC FINANCE 그룹, 알렉스 보디 부사장 선임
-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
-
Alex Bodi appointed Vice President of SCANDIC FINANCE GROUP
-
Alex Bodi, numit vicepreședinte al grupului SCANDIC FINANCE
-
Elon Musk jokes about moving businesses to space after US midterms
-
West Mercia Police opens 2027 cadet applications to Worcestershire teenagers
-
NHS to test blood screening designed to detect 13 cancers earlier
-
Worcestershire road closures announced for Remembrance Sunday events
-
Democrats near House takeover as voters judge Trump presidency
-
UBC professor describes police call after Galloway remark as act of care
-
Lethbridge submits interest in provincial ground ambulance contract
-
False voting claims spread rapidly during US Election Day
-
The Cat in the Hat expands its stakes to cosmic scale in animated reboot
-
Lettermen co-founder Tony Butala dies at 87
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
P.Sousa--PC